• Veloxis Pharmaceuticals, part of Asahi Kasei, dosed the first patient in the Phase 2 RENGEVITY-201 trial of pegrizeprument (VEL-101).
• The study tests pegrizeprument as a maintenance immunosuppressant to prevent organ rejection in de novo kidney transplant recipients.
• RENGEVITY-201 plans to enroll up to 120 patients, randomizing them 1:1:1 to two pegrizeprument doses or tacrolimus.
• Primary endpoints focus on safety, pharmacokinetics, pharmacodynamics, with efficacy assessed versus tacrolimus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.